News | Radiation Oncology | January 30, 2020

Institut Jules Bordet Invests in Elekta's Latest Cancer Treatment Technology

Renown Belgian hospital to acquire Elekta Unity MR-Linac and Versa radiation therapy systems

Elekta Unity MR Linac system

January 30, 2020 — Elekta announced that it signed a contract with the Institut Jules Bordet, Brussels, for an Elekta Unity MR-linac system, two Versa HD linear accelerators (linacs), upgrade of existing Elekta Infinity linacs as well as upgrades and expansions of Monaco treatment planning software and Mosaiq oncology information systems and service. The total contract is valued at approximately EUR 22 million, of which EUR 18 million will be booked in the third quarter of Elekta's fiscal year 2019/20. The remainder will be booked successively over the next ten years. Elekta won the contract through a public procurement procedure.

Elekta's Head of Region Europe, Renato Leite, said: "We are proud to strengthen our long-standing relationship with the Bordet Institute, which is devoted entirely to patients affected by cancer. As it prepares to move to its New Bordet Institute in 2021, we are excited to be providing the most modern radiotherapy treatment solutions available so the Institute can offer its cancer patients personalized precision radiation medicine."

The comprehensive cancer center is gearing up for its new cancer clinic with an investment in state-of-the-art technology and upgrades to existing devices. This includes Elekta Unity, a transformative magnetic resonance radiation therapy (MR/RT) system, which combines a high-field MRI scanner with a best-in-class linear accelerator to enable personalized precision radiation therapy.

The institute already enjoys Elekta solutions, including Leksell Gamma Knife Icon and two Elekta Infinity linacs as well as Mosaiq and Monaco and Elekta's microSelectron brachytherapy afterloading platform. The two Versa HD systems in this contract will replace competing systems. When all the solutions will have been deployed the Jules Bordet Institute will be Belgium's the largest single radiation therapy site with four Elekta linacs, one Unity MR-Linac and one Leksell Gamma Knife.

Software upgrades are scheduled for delivery during 2020 and the linear accelerators, including Unity, in 2021.

For more information: www.elekta.com

Related Content

An example of the MRI scans showing long-term and short-term survival indications. #MRI

An example of the MRI scans showing long-term and short-term survival indications. Image courtesy of Case Western Reserve University

News | Magnetic Resonance Imaging (MRI) | February 21, 2020
February 21, 2020 — ...
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.
Nuclear imaging equipment growth in 2020
News | Nuclear Imaging | February 14, 2020
February 14, 2020 — The nuclear imaging equipment
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
The radiation therapy market is projected to grow in through 2026

Image courtesy of Accuray

News | Proton Therapy | February 10, 2020
February 10, 2020 — Amid technological advancement, and notable research and development activities, the global ...
SIR President Laura Findeiss, M.D., FSIR

SIR President Laura Findeiss, M.D., FSIR

News | Interventional Radiology | February 09, 2020
February 9, 2020 — For some patients, kidney cancer can be effectively treated without surgery, according to the...
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
Purdue University-discovered fluorescent markers to target and illuminate cancer during surgery, has announced the results of a multi-institutional Phase 2 clinical trial in which outcomes were improved for 26 percent of patients undergoing pulmonary resection for non-small-cell lung cancer (NSCLC)

A Purdue discovery being developed by On Target Laboratories Inc., illuminates lung cancer cells on a patient during surgery. The “fluorescent markers” help medical professionals identify and remove cancer cells during surgery and is shown to improve outcomes. The technology is beginning Phase 3 clinical trials. (Photo provided by On Target)

News | Molecular Imaging | February 06, 2020
February 6, 2020 — ...
The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy

An oxygen map image recovered from a mouse undergoing radiation therapy. The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy (red). Image courtesy of Brian Pogue, PhD

News | Radiation Therapy | February 03, 2020
February 3, 2020 — Oxygen in cancer tumors is known to be a major factor that helps radiation therapy be successful.